维纳卡兰在心房颤动治疗中的应用

Application of vernakalant in the treatment of atrial fibrillation

维纳卡兰是转复新近发生心房颤动(AF)的首个心房选择性抗心律失常药物,为钠/钾通道双重阻断剂,疗效优于胺碘酮,是临床AF治疗的新策略,但尚需其与伊布利特等新药疗效对照的更为深入的研究。本文综述近年相关临床应用研究进展。

The rising incidence of atrial fibrillation（AF） has driven research to identify novel therapeutic options. Vernakalant is the first atrial-specific antiarrhythmic drug developed for pharmacological cardioversion of recent-onset AF. It is a mixed atrial selective Na＋ and K＋ channel blocker. Vernakalant has been shown to be more effective than amiodarone. However, more comparisons with existing agents are still required. This review describes the application of vernakalant in AF.